









市場行情
/
股票
/
nasdaq-lgnd
/

Ligand Pharmaceuticals Inc

LGND

200.330USD

+1.920+0.97%

收盤 12/19, 16:00（美東）報價延遲15分鐘

3.94B總市值

83.64本益比TTM



Ligand Pharmaceuticals Inc

200.330

+1.920+0.97%

概覽公司財務分析

概覽

公司

財務

分析

關於 Ligand Pharmaceuticals Inc 公司

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. It does this by financing, licensing its technologies or both. It operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. It has multiple alliances, licenses and other business relationships with various pharmaceutical companies.

Ligand Pharmaceuticals Inc簡介



公司代碼LGND

公司名稱Ligand Pharmaceuticals Inc

上市日期Nov 18, 1992

CEODavis (Todd C)

員工數量68

證券類型Ordinary Share

年結日Nov 18

公司地址555 Heritage Drive, Suite 200

城市JUPITER

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編33458

電話18585507500

網址https://www.ligand.com/

公司代碼LGND

上市日期Nov 18, 1992

CEODavis (Todd C)

Ligand Pharmaceuticals Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Jason M. Aryeh

Independent Director

129.19K

+1.60%

Dr. John W. Kozarich ,Ph.D.

Independent Chairman of the Board

42.97K

-1.08%

Dr. Stephen L. Sabba, M.D.

Independent Director

35.05K

+3.57%

Dr. John L. Lamattina, Ph.D.

Independent Director

31.98K

Mr. Andrew Reardon

Chief Legal Officer

15.72K

-7.77%

Dr. Nancy Ryan Gray, Ph.D.

Independent Director

9.35K

Mr. Octavio (Tavo) Espinoza

Chief Financial Officer

8.26K

-18.40%

Mr. Jason Haas

Independent Director

6.86K

+21.40%

Dr. Martine Zimmermann, Pharm.D.

Independent Director

4.17K

-2.68%

Mr. Todd C. Davis

Chief Executive Officer, Director

名稱

名稱/職務

職務

持股

持股變動

Mr. Jason M. Aryeh

Independent Director

129.19K

+1.60%

Dr. John W. Kozarich ,Ph.D.

Independent Chairman of the Board

42.97K

-1.08%

Dr. Stephen L. Sabba, M.D.

Independent Director

35.05K

+3.57%

Dr. John L. Lamattina, Ph.D.

Independent Director

31.98K

Mr. Andrew Reardon

Chief Legal Officer

15.72K

-7.77%

Dr. Nancy Ryan Gray, Ph.D.

Independent Director

9.35K

收入明細

單位: USD更新時間: 10月6日週一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

業務USD

名稱

營收

佔比

Kyprolis

8.80M

18.48%

Captisol

8.29M

17.40%

Filspari

6.58M

13.81%

Qarziba

5.88M

12.36%

Royalties Other

5.43M

11.41%

其他

12.64M

26.54%

由於公司未披露，未能獲取相關數據

業務

地區

業務USD

名稱

營收

佔比

Kyprolis

8.80M

18.48%

Captisol

8.29M

17.40%

Filspari

6.58M

13.81%

Qarziba

5.88M

12.36%

Royalties Other

5.43M

11.41%

其他

12.64M

26.54%

股東統計

更新時間: 11月20日週四

持股股東

股東類型

持股股東

佔比

BlackRock Institutional Trust Company, N.A.

13.35%

The Vanguard Group, Inc.

10.53%

Janus Henderson Investors

5.30%

Nomura Investment Management Business Trust

3.82%

State Street Investment Management (US)

3.81%

其他

63.21%

持股股東

佔比

BlackRock Institutional Trust Company, N.A.

13.35%

The Vanguard Group, Inc.

10.53%

Janus Henderson Investors

5.30%

Nomura Investment Management Business Trust

3.82%

State Street Investment Management (US)

3.81%

其他

63.21%

股東類型

持股股東

佔比

Investment Advisor

59.79%

Investment Advisor/Hedge Fund

39.05%

Research Firm

3.68%

Individual Investor

2.27%

Pension Fund

1.68%

Bank and Trust

1.63%

Hedge Fund

0.72%

Sovereign Wealth Fund

0.10%

Venture Capital

0.04%

機構持股



更新時間: 10月5日週日

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

541

20.07M

102.40%

-232.93K

2025Q2

535

19.71M

102.13%

-738.05K

2025Q1

554

19.82M

102.82%

-711.89K

2024Q4

546

19.28M

100.16%

-1.51M

2024Q3

543

19.17M

104.83%

-583.22K

2024Q2

527

18.31M

101.74%

-865.78K

2024Q1

520

17.60M

99.35%

-393.03K

2023Q4

527

16.97M

97.29%

-861.76K

2023Q3

515

17.24M

99.38%

-910.17K

2023Q2

526

17.09M

98.94%

-1.02M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

BlackRock Institutional Trust Company, N.A.

2.65M

13.55%

-19.35K

-0.72%

Jun 30, 2025

The Vanguard Group, Inc.

2.08M

10.64%

+33.19K

+1.62%

Jun 30, 2025

Janus Henderson Investors

1.06M

5.41%

+33.19K

+3.23%

Jun 30, 2025

Nomura Investment Management Business Trust

926.55K

4.73%

+20.33K

+2.24%

Jun 30, 2025

State Street Investment Management (US)

749.75K

3.83%

+22.63K

+3.11%

Jun 30, 2025

Congress Asset Management Company, LLP

647.94K

3.31%

+5.23K

+0.81%

Jun 30, 2025

Chicago Capital, LLC

571.83K

2.92%

+17.31K

+3.12%

Jun 30, 2025

Stephens Investment Management Group, LLC

604.81K

3.09%

-2.41K

-0.40%

Jun 30, 2025

MFS Investment Management

339.74K

1.73%

+61.95K

+22.30%

Jun 30, 2025

Dimensional Fund Advisors, L.P.

704.52K

3.6%

-40.41K

-5.42%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Franklin Genomic Advancements ETF

4.21%

Invesco Pharmaceuticals ETF

3.2%

State Street SPDR S&P Pharmaceuticals ETF

3.01%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

2.74%

Virtus LifeSci Biotech Products ETF

2.67%

Invesco S&P SmallCap Health Care ETF

2.3%

Pacer US Small Cap Cash Cows Growth Leaders ETF

1.73%

Invesco Dorsey Wright Healthcare Momentum ETF

1.64%

iShares U.S. Pharmaceuticals ETF

1.38%

First Trust Multi-Manager Small Cap Opportunities ETF

1.09%

Franklin Genomic Advancements ETF

佔比4.21%

Invesco Pharmaceuticals ETF

佔比3.2%

State Street SPDR S&P Pharmaceuticals ETF

佔比3.01%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

佔比2.74%

Virtus LifeSci Biotech Products ETF

佔比2.67%

Invesco S&P SmallCap Health Care ETF

佔比2.3%

Pacer US Small Cap Cash Cows Growth Leaders ETF

佔比1.73%

Invesco Dorsey Wright Healthcare Momentum ETF

佔比1.64%

iShares U.S. Pharmaceuticals ETF

佔比1.38%

First Trust Multi-Manager Small Cap Opportunities ETF

佔比1.09%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Ligand Pharmaceuticals Inc的前五大股東是誰？



Ligand Pharmaceuticals Inc的前五大股東如下：
BlackRock Institutional Trust Company, N.A.
持有股份：2.65M
佔總股份比例：13.55%。
The Vanguard Group, Inc.
持有股份：2.08M
佔總股份比例：10.64%。
Janus Henderson Investors
持有股份：1.06M
佔總股份比例：5.41%。
Nomura Investment Management Business Trust
持有股份：926.55K
佔總股份比例：4.73%。
State Street Investment Management (US)
持有股份：749.75K
佔總股份比例：3.83%。